A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Inclusion Criteria:

• Participants must have relapsed and refractory multiple myeloma (RRMM) withmeasurable disease

• Participants must have received at least 3 prior lines of therapy including aproteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directedmonoclonal antibody

• Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1

• Participants must have acceptable laboratory values as defined by the protocol

Exclusion Criteria:

• Participants must not have known central nervous system (CNS) involvement withmyeloma

• Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia,POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, orprimary light chain amyloidosis

• Participants cannot have ongoing acute systemic infection requiring antimicrobialtherapy

• Participants cannot require systemic steroids for any condition